Open Access“Hairy Cell Leukemia (HCL): ‘Real World’ Outcome”
Author(s) -
Archit Joshi,
Manikandan Dhanushkodi,
Prasanth Ganesan,
Venkatraman Radhakrishnan,
Krishnarathinam Kannan,
Nikita Mehra,
Jayachandran Perumal Kalaiyarasi,
S Krupashankar,
Shirley Sundersingh,
Trivadi S. Ganesan,
Tenali Gnana Sagar
Publication year - 2019
Publication title -
indian journal of hematology and blood transfusion/indian journal of hematology and blood transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.213
H-Index - 15
eISSN - 0974-0449
pISSN - 0971-4502
DOI - 10.1007/s12288-019-01199-2
Subject(s) - medicine , cladribine , hairy cell leukemia , neutropenia , malignancy , hematology , complete remission , gastroenterology , leukopenia , leukemia , pediatrics , surgery , chemotherapy
HCL is an uncommon B cell lympho-proliferative disorder with high remission rates. There is paucity of data on the long-term outcome of HCL from India. We retrospectively collected data from individual case records of patients with HCL who were treated in Cancer Institute, Chennai from January 2001 until January 2018. Sixteen patients were diagnosed with HCL and were treated with cladribine (81%), interferon (13%) and one patient received only best supportive care (6%). All the treated patients achieved complete response. More than half of the patients developed febrile neutropenia but there were no treatment related mortality. The 5-year DFS was 77% and 5-year OS was 80%. Relapse of disease was seen in 27%. HCL is a curable malignancy with high remission rates and survival comparable to patient treated in west.